Patents Assigned to Texas Biomedical Research Institute
  • Patent number: 10125173
    Abstract: The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: November 13, 2018
    Assignee: Texas Biomedical Research Institute
    Inventors: Ruth M. Ruprecht, Michael Humbert
  • Patent number: 10111881
    Abstract: Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 30, 2018
    Assignee: Texas Biomedical Research Institute
    Inventors: Robert Andrew Davey, Manu Anantpadma
  • Patent number: 9730996
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: August 15, 2017
    Assignee: Texas Biomedical Research Institute
    Inventors: Marie-Claire Gauduin, Philippe Blancou
  • Patent number: 9222142
    Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are described herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are described. Methods are described for detecting BaAdV-2/4 and BaAdV-3. Methods are also described for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: December 29, 2015
    Assignees: The Regents of the University of California, The United States of America as represented by the Secretary of the Department of Health and Human Services, Texas Biomedical Research Institute
    Inventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
  • Publication number: 20140178426
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 26, 2014
    Applicant: Texas Biomedical Research Institute
    Inventors: Marie-Claire Gauduin, Philippe Blancou